Key facts
- ARCH Venture Fund IX, L.P. filed SCHEDULE 13G/A for Sana Biotechnology, Inc. Common Stock, par value $0.0001 per share (SANA).
- Disclosed ownership: 17%.
- Date of event: 30 Sep 2025.
ARCH Venture Fund IX, L.P. - 30 Sep 2025 SCHEDULE 13G/A Report for Sana Biotechnology, Inc. Common Stock, par value $0.0001 per share (SANA)
- Symbol
- SANA
- Shares outstanding
- 266,434,249 shares
- Disclosed shares
- 46,093,125 shares
- Ownership percentage
- 17%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Nov 2025, 16:30:04 UTC
- Event date
- 30 Sep 2025
- SEC filing
- View on sec.gov
Subject security
Ownership signal
SEC evidence
Key filing fact
ARCH Venture Fund IX, L.P. disclosed 17% ownership in Sana Biotechnology, Inc. Common Stock, par value $0.0001 per share (SANA) on 30 Sep 2025.
Change
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Nov 2025, 16:30.
Research use
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Reporting managers (15)
Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| ARCH Venture Fund IX, L.P. | 17% | 45,860,681 | 0 | 45,860,681 | /s/ ARCH Venture Partners IX, L.P. | its General Partner | |
| ARCH Venture Fund IX Overage, L.P. | 17% | 45,860,681 | 0 | 45,860,681 | /s/ ARCH Venture Partners IX Overage, L.P. | its General Partner | |
| ARCH Venture Fund X, L.P. | 17% | 45,860,681 | 0 | 45,860,681 | /s/ ARCH Venture Partners X, L.P. | its General Partner | |
| ARCH Venture Fund X Overage, L.P. | 17% | 45,860,681 | 0 | 45,860,681 | /s/ ARCH Venture Partners X Overage, L.P. | its General Partner | |
| ARCH Venture Partners IX, L.P. | 17% | 45,860,681 | 0 | 45,860,681 | /s/ ARCH Venture Partners IX, LLC | its General Partner | |
| ARCH Venture Partners IX Overage, L.P. | 17% | 45,860,681 | 0 | 45,860,681 | /s/ ARCH Venture Partners IX, LLC | its General Partner | |
| ARCH Venture Partners X Overage, L.P. | 17% | 45,860,681 | 0 | 45,860,681 | /s/ ARCH Venture Partners X, LLC | its General Partner | |
| ARCH Venture Partners X, L.P. | 17% | 45,860,681 | 0 | 45,860,681 | /s/ ARCH Venture Partners X, LLC | its General Partner | |
| ARCH Venture Partners IX, LLC | 17% | 45,860,681 | 0 | 45,860,681 | /s/ Mark McDonnell | Mark McDonnell as Attorney-in-Fact for Keith Crandell, Managing Director | |
| ARCH Venture Partners X, LLC | 17% | 45,860,681 | 0 | 45,860,681 | /s/ Mark McDonnell | Mark McDonnell as Attorney-in-Fact for Keith Crandell, Managing Director | |
| Keith Crandell | 17% | 45,860,681 | 0 | 45,860,681 | /s/ Mark McDonnell | Mark McDonnell as Attorney-in-Fact for Keith Crandell | |
| Clinton Bybee | 17% | 45,860,681 | 0 | 45,860,681 | /s/ Mark McDonnell | Mark McDonnell as Attorney-in-Fact for Clinton Bybee | |
| Robert Nelsen | 17% | 46,093,125 | 232,444 | 45,860,681 | /s/ Mark McDonnell | Mark McDonnell as Attorney-in-Fact for Robert Nelsen | |
| Steven Gillis | 17% | 45,860,681 | 0 | 45,860,681 | /s/ Mark McDonnell | Mark McDonnell as Attorney-in-Fact for Steven Gillis | |
| Kristina Burow | 17% | 45,860,681 | 0 | 45,860,681 | /s/ Mark McDonnell | Mark McDonnell as Attorney-in-Fact for Kristina Burrow |
CIK / CUSIP context first